Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Axsome Therapeutics (AXSM) Return on Equity (2022 - 2025)

Axsome Therapeutics' Return on Equity history spans 4 years, with the latest figure at 2.26% for Q4 2025.

  • For Q4 2025, Return on Equity rose 157.0% year-over-year to 2.26%; the TTM value through Dec 2025 reached 2.26%, up 157.0%, while the annual FY2025 figure was 2.52%, 21.0% down from the prior year.
  • Return on Equity for Q4 2025 was 2.26% at Axsome Therapeutics, up from 3.13% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.74% in Q3 2023 and bottomed at 5.05% in Q1 2025.
  • The 4-year median for Return on Equity is 2.26% (2025), against an average of 2.4%.
  • The largest YoY upside for Return on Equity was 157bps in 2025 against a maximum downside of -328bps in 2025.
  • A 4-year view of Return on Equity shows it stood at 1.4% in 2022, then increased by 26bps to 1.04% in 2023, then crashed by -269bps to 3.83% in 2024, then surged by 41bps to 2.26% in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Return on Equity are 2.26% (Q4 2025), 3.13% (Q3 2025), and 3.91% (Q2 2025).